Q-omics provides the consensus-scored TIMM9P1 profile across patient tissues and cancer cell-line models. TIMM9P1 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, TIMM9P1 is differentially expressed in 4, with the highest sampling consensus in STAD. Additionally, TIMM9P1 RNA expression shows 7,397 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight BLCA, STAD, and LUAD as cancer lineages where TIMM9P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TIMM9P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TIMM9P1 survival associations across molecular data types. TIMM9P1 RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TIMM9P1 RNA expression–survival associations across cancer types. High TIMM9P1 expression shows unfavorable associations in BLCA, LIHC, STAD, TGCT and KIRP, but favorable associations in SKCM. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .017). Together, the overview and detailed table identify BLCA as the clearest survival context for TIMM9P1 RNA expression.
This table summarizes TIMM9P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for TIMM9P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TIMM9P1 shows lower tumor expression in UCEC and higher tumor expression in STAD, BRCA and KICH. The STAD box plot shows higher TIMM9P1 RNA expression in tumor versus normal tissue (log2 FC = +0.261, t-test p = .019).
This table shows molecular features associated with TIMM9P1 in patient tissues and cancer cell lines. In patient samples, TIMM9P1 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set.
